The Simplification of the EU MDR: What MedTech Needs to Know
|
The Simplification of the EU MDR: What MedTech Needs to Know
The European Medical Device Regulation (EU MDR) continues to present challenges for quality and regulatory teams, as well as for the medical device industry more broadly, years after its publication. The updated legislation was introduced with the objective to improve patient safety and harmonize regulatory standards across EU Member States.
Four years after the initial date of application of the regulation, the medical technology industry has gained enough experience to assess its practical impact. While the regulation has strengthened oversight and transparency, it has also introduced complexity, capacity constraints, and unintended consequences that affect product development and market access.
The European Commission has recently proposed a simplification of the EU MDR, supported by a targeted evaluation of both its successes and its limitations. In the following sections, we review the regulation’s background, summarize the key findings of the recent evaluation, and outline practical steps organizations can take to adapt to evolving regulatory expectations.
A Brief History Of The EU MDR
To understand the current regulatory climate, we must look at the system that preceded it. The Medical Device Directives governed the European market since the 1990s. While effective for a time, serious safety events exposed critical flaws in the system. High-profile incidents involving industrial-grade silicone in breast implants and complications with metal-on-metal hip replacements made it clear that the directives lacked sufficient clinical oversight.
The European Union responded by adopting the MDR in 2017, aiming to ensure that only safe, performant devices reached patients. The new framework sought to create a robust, transparent, predictable, and sustainable regulatory environment. It introduced several major changes:
- Stricter requirements for clinical evidence and post-market surveillance.
- More rigorous criteria for the designation and oversight of notified bodies.
- The establishment of the European database on medical devices (EUDAMED) to improve traceability.
- The introduction of the Unique Device Identification (UDI) system.
- The regulation officially applied in May 2021, but the scale of these changes brought significant growing pains for the industry.
Assessing The Current State Of The EU MDR
The recent European Commission Staff Working Document Evaluation of medical and diagnostic device regulations for the proposal to simplify and lessen regulatory burdens provides a comprehensive look at how the regulation operates today. The findings show a mixed reality. The framework successfully strengthened safety protocols, and vigilance activities increased significantly, giving authorities better tools to detect and manage risks. However, the implementation revealed severe bottlenecks that constrain market functioning.
Innovation And Competitiveness Challenges
The regulation places massive administrative burdens on medical device manufacturers. The assessment highlights that small and medium-sized enterprises are facing disproportionately high compliance costs. Manufacturers reported expenses of approximately €30,000–€250,000 per clinical evaluation, depending on device class and study complexity, with the highest costs incurred for Class III devices. The heavy financial and administrative toll forced many companies to divert resources away from research and development, slowing the pace of innovation. Consequently, some developers began prioritizing market launches in regions with more predictable regulatory pathways, such as the United States.
Notified Body Bottlenecks
Notified body capacity became a major hurdle early in the transition. Lengthy designation processes and extensive documentation requirements led to certification delays lasting 13 to 24 months. These delays threaten the availability of critical medical technologies. To prevent widespread market shortages, the European Commission extended the transition periods to December 2027 for legacy high-risk devices and December 2028 for legacy medium-risk devices.
Transparency And Predictability Gaps
While the regulation aimed to improve legal certainty, stakeholders still struggle with ambiguous definitions and inconsistent applications of the rules. The Medical Device Coordination Group issued over 100 guidance documents, but practical implementation challenges and differences in interpretation persist, making operational clarity harder to achieve in some areas. Furthermore, the slow rollout of EUDAMED delayed the intended transparency goals. Without the fully mandatory database in place, manufacturers continued to grapple with fragmented national registration systems.
The Threat To Orphan Devices
The assessment explicitly noted the threat to niche and orphan devices. Because these products serve small patient populations, they generate lower revenue. The high cost of gathering new clinical data under the MDR led some manufacturers to discontinue these essential devices, posing a direct risk to vulnerable patient groups.
RELATED: LEX Diagnostics Boosts Efficiency by Modernizing its Requirements Tool with Jama Connect®
The Push For Simplifying The EU MDR
Acknowledging these significant challenges, the European Commission concluded that the regulatory framework requires targeted adjustments. The upcoming simplification revision of the EU MDR, proposed in December 2025, aims to restore European competitiveness and support innovation without sacrificing patient safety.
The simplification effort focuses on reducing unnecessary administrative complexity and creating a more proportionate system. Regulatory bodies plan to streamline reporting obligations and eliminate overlapping assessments. This includes creating tailored requirements for low-risk devices and well-established technologies, which currently face burdens disproportionate to their actual risk profiles.
For niche and orphan devices, the European Commission intends to develop flexible regulatory pathways. These specialized routes will ensure that patients with rare conditions maintain access to life-saving treatments.
Another major component of the simplification is the centralization and harmonization of notified body oversight. By standardizing practices across Member States and moving away from slow, consensus-based decision making, the European Union hopes to improve predictability and reduce certification timelines. The simplification also embraces digital transformation, permanently expanding the use of electronic instructions for use and paving the way for efficient electronic submission systems.
How To Prepare For Upcoming Regulatory Changes
Preparing for regulatory shifts requires a proactive strategy. Quality and regulatory teams should take steps now to ensure a smooth transition when the simplified rules take effect.
- Audit your existing product portfolio: Identify devices that might qualify as well-established technologies or orphan devices. These products may soon benefit from streamlined regulatory pathways, saving your team significant time and resources.
- Prepare your data for EUDAMED: Although the full system experienced delays, several modules will become mandatory by May 2026. Transitioning from fragmented national databases to a centralized European system requires clean, organized, and highly accurate data.
- Establish early dialogue with your notified body: Clear communication helps you understand specific expectations and prevents misinterpretations that cause certification delays.
- Streamline your clinical evidence pipelines: Ensure your clinical evaluation reports and post-market surveillance plans are up to date. Robust data remains the foundation of compliance, even under a simplified framework.
- Upgrade your internal documentation systems: Manual documentation methods simply cannot keep pace with dynamic regulatory landscapes. Moving away from static documents is essential for maintaining compliance.
Position Your Team For Success With Jama Connect
For teams facing high process complexity and strict regulatory demands, Jama Connect offers a scalable, automated solution. Our platform streamlines traceability, enhances collaboration, and ensures compliance across global markets.
Jama Connect automates traceability and documentation processes, reducing manual effort by up to 50%. By replacing manual spreadsheets with a centralized digital platform, your team can improve risk analysis and maintain a clear line of sight from initial design requirements to final validation. This level of organization proves critical during notified body audits and helps you bring safe, compliant devices to market faster.
Whether you are a startup launching a novel device or an enterprise managing a massive global portfolio, Jama Connect accommodates your growth. The platform integrates seamlessly with your existing tools, allowing your team to focus on strategic innovation rather than administrative overhead. By modernizing your requirements management today, you position your company to navigate the simplification of the EU MDR with total confidence.
Note: This article was drafted with the aid of AI. Additional content, edits for accuracy, and industry expertise by Tom Rish and Victoria Bruno.
Solutions Consultant at Jama Software
Biomedical engineer with experience across medical device development, EU MDR clinical evaluation, and AI-enabled healthcare systems. She has contributed across the product lifecycle, from supporting clinical evidence activities for medical devices to developing software and an AI-driven research platform. Passionate about improving healthcare through practical, human-centered solutions, she currently works as a Solutions Consultant helping medical device and life sciences organizations apply systems engineering best practices and adopt Jama Software effectively.
Latest posts by Victoria Bruno (see all)
- The Simplification of the EU MDR: What MedTech Needs to Know - March 17, 2026